Wedbush assumes Oklo stock with outperform rating on nuclear progress

Wedbush initiated coverage of Oklo with an Outperform rating and a $36 price target, down from its previous $110 target; the stock was quoted at $23.52. The firm cited Oklo’s reactor reaching criticality in under 11 months and its power, fuel-recycling and isotopes businesses as differentiators. Analyst views remain mixed: TD Cowen rated the shares Hold at $26, while Canaccord Genuity maintained Buy at $100; Piper Sandler cited higher estimated capital spending when lowering its target to $49.

Analysis

The key underwriting distinction is between evidence that Oklo can execute a contained test program and evidence that it can finance, license, build, and operate repeatable commercial power plants. The Groves milestone may improve credibility with partners and regulators, but it does not by itself establish commercial economics, customer conversion, or a shorter path through project-specific approvals. Treat it as a de-risking point—not proof that the platform is ready to scale.

The target dispersion is a signal of unusually wide assumptions, not a reliable valuation range. Near-term, the Nov. 6 results are a catalyst for capex, cash-burn, and project-timing updates; the options-implied move cited in the article is direction-neutral. Over 1–3 months, financing terms and independently verifiable milestones matter more than another analyst rating. Over 6–18 months, successful conversion of development plans into permitted, funded projects would support differentiation; delays or rising plant costs would make today’s liquidity cushion less reassuring. A high current ratio does not answer how much cash a capital-intensive buildout will consume or whether future funding dilutes shareholders.

Contrarian read: the market may be assigning too little value to operating evidence relative to peers still at review stages, but the bullish case can also overgeneralize one test asset into commercial readiness. The decisive evidence is repeatability and project economics, not the rating change. No unhedged directional trade is justified solely by this coverage; use the earnings update to test the thesis.

Key Decisions for Investors

• Into Nov. 6, avoid adding on the analyst upgrade alone. Monitor reported cash burn, capex guidance, and any dated, verifiable licensing, customer, or construction milestones; the cited options move is not a directional signal.
• For investors seeking upside with capped event risk, consider a small, defined-risk OKLO call spread only after results if project milestones are intact and capex or funding needs have not worsened. Avoid specifying strikes until post-earnings implied volatility and liquidity are checked.
• Falsify the execution thesis if management pushes out key project dates, raises expected plant costs materially, or signals funding needs that threaten meaningful dilution. Reassess any bullish position on those disclosures.
• A test-reactor achievement is not evidence of commercial power margins. Require project-level cost, financing, and approval detail before underwriting the power segment; treat isotope potential as unproven until revenue contribution is disclosed.